A 58-year-old man with COPD presents with community-acquired pneumonia (CAP). He has no penicillin allergy, normal renal function, and moderate severity disease (respiratory rate 28/min, SpO₂ 88% on room air). What is the drug of choice for initial empirical therapy?

Explanation

## First-Line Treatment of Moderate CAP with Comorbidity **Key Point:** In moderate CAP with comorbidities (COPD, diabetes, chronic heart disease, or age >65 years), the standard recommendation is a **beta-lactam plus macrolide** combination or a respiratory fluoroquinolone. IV formulations are preferred for moderate-to-severe disease. ### Rationale for Correct Answer **High-Yield:** Amoxicillin-clavulanate IV (or ceftriaxone IV) + azithromycin is the guideline-recommended regimen for: - Moderate CAP with comorbidities - Coverage of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and atypical organisms (*Mycoplasma*, *Chlamydia*, *Legionella*) - IV route ensures adequate bioavailability in moderate disease **Clinical Pearl:** The addition of a macrolide (azithromycin) to a beta-lactam provides: 1. Atypical organism coverage (not covered by beta-lactams alone) 2. Potential anti-inflammatory effects 3. Improved outcomes in CAP with comorbidities ### Comparison of Options | Regimen | Indication | Limitation | |---------|-----------|----------| | **Amoxicillin-clavulanate IV + azithromycin** | Moderate CAP with comorbidities | — | | Oral amoxicillin-clavulanate alone | Mild CAP, no comorbidities | Inadequate atypical coverage; oral route unsuitable for moderate disease | | Fluoroquinolone monotherapy | Mild-to-moderate CAP without comorbidities; intolerant to beta-lactams | Less preferred as first-line for moderate disease with comorbidities | | Cefixime oral | Mild CAP only | Oral formulation; inadequate for moderate disease | **Mnemonic: "COMET" for CAP with Comorbidities** — **C**eftriaxone/**C**efotaxime or **A**moxicillin-clavulanate + **M**acrolide (azithromycin) + **E**nsure IV route + **T**reat atypicals. ### Why IV Over Oral in Moderate Disease - Respiratory rate 28/min and SpO₂ 88% indicate moderate hypoxemia - IV route ensures rapid, reliable drug levels - Oral bioavailability may be compromised in acute illness [cite:Harrison 21e Ch 297]